Tags

Type your tag names separated by a space and hit enter

Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals.
Signal Transduct Target Ther. 2020 08 14; 5(1):156.ST

Abstract

The global Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has affected more than eight million people. There is an urgent need to investigate how the adaptive immunity is established in COVID-19 patients. In this study, we profiled adaptive immune cells of PBMCs from recovered COVID-19 patients with varying disease severity using single-cell RNA and TCR/BCR V(D)J sequencing. The sequencing data revealed SARS-CoV-2-specific shuffling of adaptive immune repertories and COVID-19-induced remodeling of peripheral lymphocytes. Characterization of variations in the peripheral T and B cells from the COVID-19 patients revealed a positive correlation of humoral immune response and T-cell immune memory with disease severity. Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients. Furthermore, we also identified novel antigens that are responsive in the convalescent patients. Altogether, our study reveals adaptive immune repertories underlying pathogenesis and recovery in severe versus mild COVID-19 patients, providing valuable information for potential vaccine and therapeutic development against SARS-CoV-2 infection.

Authors+Show Affiliations

HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.Department of Infectious Diseases, Heilongjiang Provincial Hospital, Harbin Institute of Technology, Harbin, 150030, China.HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.Harbin Blood Center, Harbin, 150056, China.HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China.Centre for Reproductive Medicine, Heilongjiang Provincial Hospital, Harbin Institute of Technology, Harbin, 150030, China. Department of Obstetrics and Gynecology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.HIT Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China. huangzhiwei@hit.edu.cn.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32796814

Citation

Zhang, Fan, et al. "Adaptive Immune Responses to SARS-CoV-2 Infection in Severe Versus Mild Individuals." Signal Transduction and Targeted Therapy, vol. 5, no. 1, 2020, p. 156.
Zhang F, Gan R, Zhen Z, et al. Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. Signal Transduct Target Ther. 2020;5(1):156.
Zhang, F., Gan, R., Zhen, Z., Hu, X., Li, X., Zhou, F., Liu, Y., Chen, C., Xie, S., Zhang, B., Wu, X., & Huang, Z. (2020). Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. Signal Transduction and Targeted Therapy, 5(1), 156. https://doi.org/10.1038/s41392-020-00263-y
Zhang F, et al. Adaptive Immune Responses to SARS-CoV-2 Infection in Severe Versus Mild Individuals. Signal Transduct Target Ther. 2020 08 14;5(1):156. PubMed PMID: 32796814.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. AU - Zhang,Fan, AU - Gan,Rui, AU - Zhen,Ziqi, AU - Hu,Xiaoli, AU - Li,Xiang, AU - Zhou,Fengxia, AU - Liu,Ying, AU - Chen,Chuangeng, AU - Xie,Shuangyu, AU - Zhang,Bailing, AU - Wu,Xiaoke, AU - Huang,Zhiwei, Y1 - 2020/08/14/ PY - 2020/06/24/received PY - 2020/07/22/accepted PY - 2020/07/17/revised PY - 2020/8/16/entrez PY - 2020/8/17/pubmed PY - 2020/9/4/medline SP - 156 EP - 156 JF - Signal transduction and targeted therapy JO - Signal Transduct Target Ther VL - 5 IS - 1 N2 - The global Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has affected more than eight million people. There is an urgent need to investigate how the adaptive immunity is established in COVID-19 patients. In this study, we profiled adaptive immune cells of PBMCs from recovered COVID-19 patients with varying disease severity using single-cell RNA and TCR/BCR V(D)J sequencing. The sequencing data revealed SARS-CoV-2-specific shuffling of adaptive immune repertories and COVID-19-induced remodeling of peripheral lymphocytes. Characterization of variations in the peripheral T and B cells from the COVID-19 patients revealed a positive correlation of humoral immune response and T-cell immune memory with disease severity. Sequencing and functional data revealed SARS-CoV-2-specific T-cell immune memory in the convalescent COVID-19 patients. Furthermore, we also identified novel antigens that are responsive in the convalescent patients. Altogether, our study reveals adaptive immune repertories underlying pathogenesis and recovery in severe versus mild COVID-19 patients, providing valuable information for potential vaccine and therapeutic development against SARS-CoV-2 infection. SN - 2059-3635 UR - https://www.unboundmedicine.com/medline/citation/32796814/Adaptive_immune_responses_to_SARS_CoV_2_infection_in_severe_versus_mild_individuals_ L2 - https://doi.org/10.1038/s41392-020-00263-y DB - PRIME DP - Unbound Medicine ER -